EN
/
JP
News
About Us
About Us
Philosophy/Policy
Board of Directors
History
Company Information
Corporate Governance
Partner
Close
Business Strategy
Business Strategy
Business Model
Life Cycle Management Strategy
Close
Technology
Technology
SLC Transporters
LAT1 Inhibitors
Close
Pipeline
Pipeline
Development Status
Biliary Tract Cancer
Multiple Sclerosis
Other Pipelines
Close
Clinical Trials
Clinical Trials
Biliary Tract Cancer Phase III
JPH034 Phase 1
Close
IR
IR
IR News
Top Message
Disclosure Policy
Financial Highlights
IR Calendar
IR Library
Financial Results
Presentation Materials
IR Materials
Stock Information
Stock Overview
General Meeting of Shareholders
Disclaimer
Close
Contact
EN
/
JP
Close
Top
＞
News Lists
News Lists
All
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2025.08.25
Notice of Resignation of Representative Director Keiichi Masuya and New Management Structure
2025.07.07
J-Pharma Raises an Additional 470 Million Yen Through Third-Party Allotment and Exercise of Stock Option Rights – Total Funding Reaches Approximately 13.4 Billion Yen
2025.06.30
Notice of Board of Directors Appointments
2025.06.10
BREAKFAST MEETING for Prospective Investigators during ASCO~First Step to Start U.S. Phase III Clinical Trial of LAT1 Inhibitor NANVURANLAT for Advanced Biliary Tract Cancer~
2025.06.02
Office Relocation Notification
2025.05.23
Positive Response Received from U.S. FDA at CMC Type-C Meeting for Novel Anticancer Candidate Drug Nanvuranlat – Important progress toward the start of Phase III Clinical Trial in the U.S.
2025.04.01
J-Pharma appoints Keiichi Masuya as Representative Director and Co-CEO, and transits to a new management structure
2025.04.01
J-Pharma Raises Maximum ¥5.77 Billion in Funding Accelerates Global Development of LAT1 Inhibitors
2025.02.26
Notice of Board of Directors Appointments
2025.02.20
Announcement of presentation at the J.P. Morgan, UC Berkeley Healthcare Conference Taipei 2025
1
2
3
4
5
6
7
8
